Analyst Corner: Maintain ‘buy’ on Cipla, raise TP to Rs 1,065

By: |
May 18, 2021 2:45 AM

US on a steady growth path; sizeable launches lined up in FY23: Cipla continues to see strong traction for its gProventil (albuterol inhaler) launch in the US where it has garnered 13.2% volume share. 4Q US sales at $138 m declined 2% qoq on lack of meaningful launches.

Shares of Cipla closed at Rs 946.40 per scrip on BSE, down 0.29 per cent from its previous close.Shares of Cipla closed at Rs 946.40 per scrip on BSE, down 0.29 per cent from its previous close.

4Q miss on lower India sales and certain one-off costs: 4Q revenue of Rs 46.1 bn declined 10.9% qoq (+5.3% yoy) on lower sales in the key markets of India, the US and Ro. India sales at Rs 18.1 bn declined 19% qoq in 4Q, which is one of the seasonally weakest quarters. EBITDA margins at 17.3% declined 653 bps qoq on low gross margins and higher other operating costs. PAT at Rs 4.1 bn declined 44.7% qoq (+68.1% yoy on a low base).

US on a steady growth path; sizeable launches lined up in FY23: Cipla continues to see strong traction for its gProventil (albuterol inhaler) launch in the US where it has garnered 13.2% volume share. 4Q US sales at $138 m declined 2% qoq on lack of meaningful launches. In our view, its US sales remains on a steady growth path with improving margins on: a) continued scale-up in respiratory sales (~24% of US sales in FY21); b) visible key launches in FY22/23 (e.g. lanthanum carbonate and sumatriptan nasal spray in FY22; gRevlimid, gAbraxane and potentially gAdvair in FY23); and c) improving reach in institutional channels.

Maintain ‘buy’ on strong business outlook: Despite the 4Q miss, we maintain our positive view on Cipla for its strong outlook in focus segments like India and the US. ‘One India’ initiative led portfolio synergies should sustain outperformance of its India sales versus the market. The outlook remains steady for other key markets like the US and South Africa. Cipla is seeing rising demand for COVID-19 related products (e.g. remdesivir) and the impact should be reflected in 1QFY22.

Raise TP to Rs 1,065 (from Rs 1,055): We add NPV per share of Rs 25 for the inhalers pipeline and Rs 20 for gRevlimid (lower than earlier value of Rs 25 on higher competition) to the base business value to arrive at our fair value target price of Rs 1,065 (from Rs 1,055). We remove NPV of Rs 7/share for IV tramadol in view of uncertainty around its approval in the US.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Max Financial Services Rating: buy: Strong showing in the final quarter of fiscal
2Steel Authority of India Rating: hold: A robust performance by the company
3RPower seeks shareholders’ nod to issue of shares, warrants worth Rs 1,325 cr to RInfra